$36.00
Manufacturer: Hungary
Treatment of hypercholesterolemia
Adults, adolescents and children aged 10 years and older with primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) as an adjunct to diet when diet and other non-pharmacological measures (eg, exercise, weight loss) is insufficient.
Prevention of cardiovascular disorders
Prevention of major cardiovascular events in patients estimated to be at high risk of a first event of cardiovascular event as an adjunct to correction of other risk factors.
Description
Rozulip (rozuvastatin) coated tablets 20 mg. №28
Composition
active ingredient: rosuvastatin;
1 film-coated tablet contains 5.34 mg, or 10.68 mg, or 21.36 mg, or 42.72 mg of rosuvastatin zinc (corresponding to 5 mg, or 10 mg, or 20 mg, or 40 mg of rosuvastatin respectively);
excipients: lactose monohydrate, povidone, crospovidone, magnesium stearate, polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc.
Dosage form
Film-coated tablets.
Basic physical and chemical properties:
- 5 mg tablets: white or almost white round, slightly biconvex film-coated tablets, engraved with a stylized letter E on one side and number 591 on the other, odorless or almost odorless;
- 10 mg tablets: white or almost white round, slightly convex film-coated tablets, engraved with a stylized letter E on one side and number 592 on the other, odorless or almost odorless;
- 20 mg tablets: white or almost white round, slightly convex film-coated tablets, engraved with a stylized letter E and number 593 on one side, odorless or almost odorless;
- 40 mg tablets: white or almost white, oval, slightly biconvex film-coated tablets, engraved with a stylized letter E and number 594 on one side, odorless or almost odorless.
Pharmacological group
The drugs lower the level of cholesterol and triglycerides in the blood serum. HMG-CoA reductase inhibitors.
Code ATX C10A A07.
Pharmacological properties
This is a remedy that corrects fat metabolism. The active ingredient selectively and competitively inhibits the HMG-CoA reductase enzyme, which catalyzes the conversion of HMG-CoA into a cholesterol precursor in the liver. Promotes an increase in the number of LDL receptors on the surface of liver cells, increasing catabolism and seizure. It also slows down the production of VLDL, thereby reducing the total content of “bad fats” in the blood.
Indications
Rozucard coated tablets 20 mg. is prescribed:
- with homozygous hereditary hypercholesterolemia – as an addition to diet, other lipid-lowering pharmaceuticals;
- for the treatment of primary hypercholesterolemia (type IIa, including heterozygous hereditary hypercholesterolemia);
- for the treatment of mixed dyslipidemia (type IIb) – as an addition to the diet when non-pharmacological methods are ineffective;
- for the prevention of cardiovascular complications;
- to reduce the risk of developing severe cardiovascular complications in adults at high risk of developing them.
Contraindications
You cannot appoint Rozucard coated tablets 20 mg.:
- with intolerance to the components of the drug;
- with hepatobiliary diseases in the active phase;
- with chronic kidney disease at stages 4-5 (creatinine excretion rate <30 ml / minute);
- during pregnancy / lactation, planning pregnancy;
- with pathology of muscle tissue;
- while taking cyclosporine;
- with a predisposition to myopathy, rhabdomyolysis.
Application during pregnancy and lactation
Not applicable.
Method of administration and dosage
Rozucard coated tablets 20 mg. is taken orally whole, without chewing, with water, regardless of the meal.
The standard starting dose for the treatment of hypercholesterolemia is 5 mg or 10 mg once a day. If necessary, it is allowed to increase the dose after 4 weeks. Due to the high likelihood of side effects, increasing the dose to 40 mg should be considered only in patients with severe hypercholesterolemia, a high risk of cardiovascular complications (for example, hereditary hypercholesterolemia), when it was not possible to achieve the target values when using lower doses.
For the prevention of cardiovascular complications, 20 mg per day is indicated.
Overdose
Symptomatic therapy, control of hepatic parameters, CPK level is recommended.
Side effects:
- Blood test changes: thrombocytopenia.
- Immune disorders: allergies, including angioedema.
- Endocrine disorders: diabetes mellitus.
- Mental disorders: depression.
- Neurological disorders: headache, polyneuropathy, insomnia, dizziness, peripheral neuropathy, amnesia, nightmares.
- Respiratory disorders: shortness of breath, cough.
- Digestive Disorders: Pancreatitis, abdominal pain, nausea, constipation / diarrhea.
- Hepatobiliary disorders: jaundice, hepatitis, increased activity of liver transaminases.
- Dermatological disorders: rash, Stevens-Johnson syndrome, urticaria, pruritus.
- Musculoskeletal disorders: myalgia, rhabdomyolysis, myopathy, myositis, arthralgia, tendon rupture, immune-mediated necrotizing myopathy.
- Urinary disorders: hematuria.
- Sexual disorders: gynecomastia.
- General disorders: edema, asthenic syndrome.
Recent Reviews